• H.B. Fuller recently reported full-year 2025 results showing sales of US$3.47 billion versus US$3.57 billion a year earlier, alongside higher net income and earnings per share, and its Board declared a regular quarterly dividend of US$0.235 per share payable on February 19, 2026 to shareholders of record on February 5, 2026.
• The combination of rising profitability on slightly lower sales and the continuation of a 58-year quarterly dividend streak offers a window into how H.B. Fuller balances earnings quality with long-term capital returns.
• We will now examine how the improved earnings per share alongside the reaffirmed dividend stream influences H.B. Fuller’s investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 32 companies in the world exploring or producing it. Find the list for free.

What Is H.B. Fuller's Investment Narrative?

To own H.B. Fuller, you need to believe in a steady adhesives franchise that can convert modest top-line movement into improving earnings, while returning cash to shareholders. The latest results fit that story: sales softened slightly to about US$3.47 billion, but net income and EPS improved, and guidance points to flat to slightly higher revenue in 2026. The reaffirmed quarterly dividend at US$0.235 per share, extending a 58-year streak, signals management’s confidence in cash generation, even as revenue growth is expected to be muted. In the near term, the key catalyst is whether the company can keep lifting profitability and margins without a strong sales tailwind. At the same time, limited revenue growth and weaker cash flow coverage of debt remain important watchpoints.

However, one issue around debt coverage and growth consistency is worth a closer look for investors. Despite retreating, H.B. Fuller's shares might still be trading 23% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community cluster between about US$71.71 and US$78.36, reflecting differing expectations. Set against muted revenue guidance and debt coverage concerns, these contrasting views invite you to weigh how much earnings resilience really matters for H.B. Fuller’s long-term performance.

Explore 2 other fair value estimates on H.B. Fuller - why the stock might be worth as much as 30% more than the current price!

Build Your Own H.B. Fuller Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your H.B. Fuller research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free H.B. Fuller research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate H.B. Fuller's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.